| Autor: |
AMOL SAGDEO, AYMAN ASKARI, PATRICK BALL, HANA MORRISSEY |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
International Journal of Current Pharmaceutical Research. :27-30 |
| ISSN: |
0975-7066 |
| DOI: |
10.22159/ijcpr.2022v14i1.44109 |
| Popis: |
Fibromyalgia is a chronic health condition characterized by chronic pain fatigue, sleep disturbances and many other symptoms affecting a patient’s quality of life. Patients with fibromyalgia often visit rheumatology outpatients with a long list of symptoms and often receive multiple medications. Many have seen multiple specialists and have done a lot of reading about alternative modalities of treatment. The limited effectiveness of conventional therapy coupled with widespread media attention raises the question of cannabis use. This review examines the literature on cannabinoid use in fibromyalgia against the context of the international variation in legal frameworks, the available products and the outcomes reported. A detailed review was performed using the EMBASE and PUBMED databases. It was concluded that despite the interest in the use of cannabinoids in the management of fibromyalgia, there is insufficient evidence to prescribe the currently available licensed medicines or to recommend the complementary health products available for legal purchase. There is a need for more global clinical randomised trials to accurately determine medicinal cannabis short and long-term long efficacy and safety for its acute and chronic use. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
